Apcs, which is involved in binding microbes and activates the classical complement pathway (29–32), is reported to decline during MASLD progression (33), and its experimental administration effectively protects the steatotic liver (34). Here, APCS is linked to metabolic dysfunction-associated steatotic liver disease.